-
Cell: The next generation of gene editing technology CRISPRoff opens the surface
Time of Update: 2021-05-10
On April 9, in a paper published in Cell, researchers from the University of California, San Francisco and Massachusetts Institute of Technology developed a new type of epigenetic genome editing tool "CRISPRoff".
-
Eli Lilly closes Dermira plant to transfer hyperhidrosis drug Qbrexza
Time of Update: 2021-05-10
CompilationFan DongdongA few days ago, Eli Lilly announced that it would close its Dermira plant in Menlo Park, lay off 163 employees, and intend to sell the hyperhidrosis drug Qbrexza to Journey Medical.
-
Hengrui's 2020 financial report: revenue of 27.7 billion oncology drugs contributes 55% and PD-1 triples
Time of Update: 2021-05-10
strategy in 2020 and actively expand overseas markets. The establishment of a European clinical center in Basel, Switzerland to further improve the global innovation system will help accelerate the development of innovative
-
How do we choose the anesthesia method for labor analgesia and transfer to cesarean section
Time of Update: 2021-05-10
, and sufficient time to operate; [Advantages] Fast onset, good effect, and precise effect; [Operation suggestion] Choose a puncture below the epidural catheter, optional Local anesthetics include 15-20mg of ropivacaine and 10-12mg of bupivacaine
-
Live broadcast preview | Promote the rational use of drugs and standardize anti-cancer treatment online kick-off meeting to be held soon
Time of Update: 2021-05-10
>
The "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)" formulated by the National Health Commission was issued on December 22, 2020, and the measures
-
Nursing safety is no small matter
Time of Update: 2021-05-10
for compensation for the death of the patient.
>
1. Questions about the cause of this case.
>
According to the “Regulations on Causes of Civil Cases
-
Professor Wang Luhua: Ibrutinib combined regimen brings long-term significant survival benefits for newly treated MCL patients
Time of Update: 2021-05-10
IR sequential R-HCVAD treatment of young (<65 years old) newly-treated MCL patients, the 5-year PFS rate reached 66%, Professor Luhua Wang introduced that the WINDOW-1 study included a total of 131 young newly-treated MCL patients (median age of 56).
-
Johnson & Johnson's new indication for daratumumab is about to be approved in China
Time of Update: 2021-05-10
Although many progresses have been made in the treatment of multiple myeloma in recent years, most patients still face the problem of relapse or drug resistance.
-
Johnson & Johnson CD38 monoclonal antibody new indication approved in China, sales of 4.19 billion U.S. dollars in 2020
Time of Update: 2021-05-10
Although many progresses have been made in the treatment of multiple myeloma in recent years, most patients still face the problem of relapse or drug resistance.
-
Hengrui CDK4/6 inhibitor is reported to be listed and plans to be included in priority
Time of Update: 2021-05-10
On December 24 last year, Hengrui announced that SHR6390 combined with fulvestrant in the treatment of HR-positive, HER2-negative, locally advanced or advanced breast cancer after endocrine therapy has reached the primary research endpoint.
-
Mindray's 2020 financial report: revenue of 21.026 billion and net profit increased by 42%. Research
Time of Update: 2021-05-10
026 billion yuan, a year-on-year increase of 27%; the net profit attributable to shareholders of listed companies in 2020 is approximately 6.
-
FDA opens a new era of mandatory enforcement of regenerative medicine therapy and stricter supervision is coming
Time of Update: 2021-05-10
Center for Biological Products Review and Research (CBER), said that the time is up and there will be no further delays. A new era of law enforcement will begin on June 1. Marks said, “Although the FDA
-
Major update of ASCO guidelines: Recommended initial treatment for metastatic non-castrated prostate cancer
Time of Update: 2021-05-10
In the past, ASCO has issued clinical practice guidelines for the initial hormone therapy of non-castrated
-
Kangfang Bio-PD-1/CTLA-4 Dual Antibody Approved Global Phase 3 Clinical First-line Treatment for Advanced Cervical Cancer
Time of Update: 2021-05-10
that cadonilimab has significantly reduced toxicity compared with the combination therapy of PD-1 antibody and CTLA-4 antibody, and has obvious safety and efficacy advantages.
>
Based on good clinical data, in August
-
FDA expert group 7:2 supports the retention of Tecentriq triple-negative breast cancer
Time of Update: 2021-05-10
In March 2019, PD-L1-positive patients' progression-free survival (PFS) results based on the IMpassion130 study of atelizumab combined with Abraxane (albumin paclitaxel) in the treatment of PD-L1-positive metastatic triple-negative breast cancer (TNBC) (7.
-
Interpretation of the Chinese Guidelines for Diabetic Nephropathy (Part 1), full of dry goods
Time of Update: 2021-05-10
Studies have shown that diabetic patients with normal proteinuria show a progressive decline in renal function after CKD3, which is why eGFR<60 ml/(min·1.
-
How to avoid severe hypoglycemia in elderly patients with type 2 diabetes who started insulin
Time of Update: 2021-05-10
Comment In this study, compared with NPH insulin, the use of long-acting insulin analogues (insulin glargine or insulin detemir) in elderly patients with type 2 diabetes is associated with a lower risk of severe hypoglycemia.
-
Abdominal pain, black stools for half a month, the patient lost 10 kg...Where is the bleeding
Time of Update: 2021-05-10
This patient has a clear diagnosis of gastrointestinal bleeding, low hemoglobin, anemia, gastroscopy, colonoscopy, and capsule endoscopy for normal procedures.
-
Stones from Other Mountains | Experience Sharing of the Latest Approved PK Software (1): Spanish Experience
Time of Update: 2021-05-10
treatment, the complexity of traditional PK testing makes PK-guided individualized preventive treatment unable to be widely and practically applied. PK software came into being: Based on the above situation, PK tools
-
Roche's oncology business continued to be impacted by biosimilars in the first quarter, and total sales fell by 19
Time of Update: 2021-05-10
Avastin's sales during the quarter fell sharply by 42% to 863 million Swiss francs.
